A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)

Hanmi Pharmaceutical Company Limited41 enrolled

Overview

Single ascending dose of HM15211 in healthy obese subjects.

A First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics after single ascending dose of HM15211 in healthy obese subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Obesity

Interventions

HM15211 or PlaceboBIOLOGICAL

Long-acting tri-agonist

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Female subjects must be non-pregnant and non-lactating Exclusion Criteria: * Participation in an investigational study within 30 days prior to dosing

Locations (1)

Hanmi Investigative Site

Chula Vista, California, United States

Outcomes

Primary Outcomes

Number of Participants With Adverse Events

An adverse event is any undesirable and unintended medical event occurring to a subject in a clinical study, whether or not related to the investigational products

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.